尼莫地平对伴轻度认知功能损害2型糖尿病患者早期防治初探

A priliminary study on the prevention and early treatment of Nimodipine for type 2 diabetes mellitus with mild cognitive impairment

以蒙特利尔认知评估量表（MoCA）、脑诱发电位失匹配负波（MMN）为工具选取98例2型糖尿病合并轻度认知功能损害患者。选择其中48例患者在常规治疗同时给予尼莫地平20mg/d（用药组），观察与其他50例患者（对照组）18个月后MoCA、MMN的变化。两组间MoCA评分未见明显差异（P〉O．05）。用药组MMN的潜伏期、波幅较治疗前改善，差异有统计学意义（P〈0．05）；对照组MMN的波幅较治疗前进一步降低，差异有统计学意义（P〈0．05），但MMN潜伏期治疗前后没有显著性差异（P〉0．05）。

Ninty-eight patients of type 2 diabetes mellitus with mild cognitive impairment were collected according to the Montreal Cognitive Assessment （MoCA）and mismatch neativity（MMN）.Forty-eight patients were assigned to conventional treatment with nimodipine（20 mg/d）.The MoCA and MMN were evaluated and compared with the remaining 50 patients who served as a control group.There was no significant difference between two patient groups in MoCA（P〉0.05）;the latency and amplitude of MMN were significantly improved in the treated group（P〈0.05）;the amplitude of MMN was reduced in control group（P〈0.05）,but the latency of MMN showed no significant change（P〉0.05）.